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Abstract
Introduction and hypothesis Unsatisfactory treatment out-
come sometimes is described as frequently occurring in pa-
tients treated with first-line therapy for overactive bladder
(OAB). The present article reviews the different circum-
stances which may result in failure to respond to lifestyle
interventions, behavioral therapy, and/or antimuscarinic
treatment.
Methods An extensive literature search was conducted to
identify relevant articles on pathophysiological, clinical, and
pharmacological aspects of refractory OAB.
Results Missing definition, unrealistic individual expectation
of treatment outcomes, lack of communication between physi-
cian and patient as well as pathophysiological and pharmaco-
logical processes were identified as relevant for failure to re-
spond to first-line OAB treatment. Increase of patient’s motiva-
tion to adhere to the prescribed treatment, critical examination
of the patient in regard to the initial diagnosis, and individual
adjustment of antimuscarinic therapy may be appropriate tools
to improve treatment outcome in OAB patients.
Conclusions Overall, the incidence of refractory OAB seems
to be overestimated. There are several approaches to improve
therapy results.
Keywords Refractory OAB . Treatment . Antimuscarinic .
Pathophysiology . Pharmacology
Introduction
Lifestyle interventions and behavioral therapies, which may
be combinedwith antimuscarinic treatment, are recommended
in international guidelines as first-line therapy for patients
with overactive bladder (OAB) [1, 2]. Failure to respond to
conservative and pharmacological treatment of OAB has pre-
viously been described [3], but there is considerable heteroge-
neity in the definitions of both treatment response and nonre-
sponse in trials involving patients with OAB [4]. Over the last
few years several clinical studies have been published which
investigated different pharmacological principles (e.g., other
antimuscarinic drugs, beta-3 agonists, botulinum toxin) and
strategies (increasing anticholinergic doses, additional treat-
ment with other anticholinergic drugs, or beta-3 agonists) in
the treatment of patients with refractory OAB [5–10]. The vast
majority of these studies report significant improvement of
OAB symptoms following a change in treatment. In this re-
view we discuss published data concerning factors which may
be behind refractory OAB in order to aid in understanding
different treatment results in OAB patients.
Materials and methods
Computerized library systems such as MEDLINE, BIOSIS,
and EMBASE were analyzed regarding articles on refractory
OAB published between 2000 and 2014. Search terms includ-
ed Boveractive bladder^ or Bdetrusor overactivity^ or
Bantimuscarinic^ AND Bnon-responder,^ or Brefractory,^ or
Bfail,^ or Bpersistent,^ or Bdissatisfied.^ Furthermore, reviews
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of pharmacological and physiological aspects were carried out
using the same first two search terms combined with terms
such as Bmuscarinic,^ Bnicotinic,^ Bm-receptor,^ Badrenergic,
^ and Btransporters.^ In addition, unpublished pharmacologi-
cal and clinical data were included.
Results
The missing definition
Refractory OAB patients most likely represent a minority of
the total OAB population, but the epidemiology is unknown
[11]. As shown byGoldman et al., a wide variety of symptom-
based definitions and patient-reported outcomes with incon-
sistent thresholds are used in the published literature to decide
whether or not patients respond to conservative and/or
antimuscarinic treatment [4]. Moreover, patients’ individual
evaluation of treatment success is characterized by different
expectations and perceptions [4]. Accordingly, patients’ state-
ments on failure of antimuscarinic treatment are diverse. A
large-scale study involving 5,392 patients showed that
46.2 % of those who reported discontinuing one or more
antimuscarinic OAB medications gave the reason for this that
the treatment Bdid not work as expected,^ in 25.1 % medica-
tion was switched, 23.3 % Blearned to get by without medica-
tion,^ and 21.1 % discontinued due to side effects [12]. The
current American Urological Association (AUA) and Europe-
an Association of Urology (EAU) guidelines on urinary in-
continence contain recommendations for the treatment of re-
fractory OAB [1, 2], but no definitions of criteria and/or
thresholds to assess unsatisfactory outcomes of therapy were
described.
Physician’s expectations
Current clinical studies in patients with refractory OABwhose
behavioral and/or antimuscarinic treatment was stopped due
to lack of efficacy or side effects and replaced by alternative
medication (e.g., botulinum toxin A, other antimuscarinics,
beta-3 agonists) are summarized in Table 1. When assessing
the results of these studies concurrently, it becomes clear that
definitions of Bantimuscarinic failure^ are based on inconsis-
tent criteria ranging from the somewhat subjective evaluation
Black of benefit or intolerable side effects^ to the strict prereq-
uisite of B≥1 UUI/day.^ This corresponds with the observa-
tions made by Goldman et al. in their systematic review [4]. If
the criteria for diagnosis of refractory OAB used in these stud-
ies are compared with those defined for success in the changed
treatment studies (Table 1), it becomes obvious that the latter
criteria often seem to be less strict [6, 13–15]. If the same strict
criteria of>1 UUI day, as was chosen for inclusion into the
study by Kanagarajah et al. [15] and Kuo [13], had been
defined as the response following secondary therapy, practi-
cally no patients could be classified as a responder in the
described clinical studies with botulinum toxin A. This dem-
onstrates that the physician’s individual expectations may be
highly relevant in differentiating between responders and non-
responders to primary OAB treatment. In practice, complete
cure of OAB symptoms under first-line treatment is rare [16],
and even after second-line treatment with botulinum toxin and
neuromodulation the proportion of patients showing improve-
ment of symptoms rather than total cure is greater [17, 18].
Patients’ motivation and expectations
Essential for treatment response to OAB treatment is adher-
ence to the prescribed therapy. Although it seems mundane,
during both conservative and antimuscarinic treatment, realis-
tic information provided to the patient on possible treatment
efficacy, and on side effects, and additionally the quality of the
course for lifestyle modification and behavioral bladder
retraining, are essential to reach adherence to the prescribed
treatment [1, 16]. Lifestyle modification should include stop-
ping smoking and limiting the intake of caffeine, alcohol, and
carbonated and citrus beverages, which may lead to an in-
crease in OAB symptoms [16, 19].
Indeed, inadequate follow-up after initiation of therapy
(poor motivation) and unmet or unrealistic expectations (poor
communication between patients and the physician) have
been identified as contributory factors to nonadherence, in
addition to adverse events and insufficient beneficial effects
[20]. Jundt et al. demonstrated in their survey that 10 % of
patients with OAB had not started with the medication
12 months after prescription because of their Bfear of side
effects^ or did Bnot want to take pills^ [21]. In this study, most
patients stopped taking the medication without discussing the
issue with their doctor. Swartz and Vasavada assume that
many patients may be prematurely labeled as having refracto-
ry OAB after only a modest attempt at medical or behavioral
treatment [11]. Consequently, regular follow-ups to monitor
treatment effects and adherence may be useful [16] as well as
providing realistic information on symptom improvements as
expected treatment success and on any side effects which may
occur.
Pathophysiological reasons
OAB is a symptom complex rather than a disease. Lack of
efficacy of treatment with antimuscarinics as well as with
behavioral bladder retraining, may be associated with under-
lying causes for lower urinary tract dysfunction which may
have been overlooked in previous examinations. In order to
exclude any other causes, repeated examinations of bacterial
cystitis, painful bladder, voiding dysfunction, bladder or pel-
vic tumors, calculus, atrophic vaginitis, vaginal prolapse,
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medication side effects, neurological reasons, polyuria (poly-
dipsia, diabetes mellitus/insipidus, chronic renal failure, and
hyperthyroidism) should be considered [1, 22, 23].
Digesu et al. investigated 110 women with refractory OAB
by cystoscopy and biopsy [24]. The patients had undergone
conservative management (lifestyle change, bladder
retraining, and physiotherapy) and previous treatment with
two ormore antimuscarinics. Among the patients, histopathol-
ogy showed chronic cystitis in 94, follicular cystitis in 3, acute
and chronic cystitis in 2, transitional cell carcinoma in 6, and
no abnormality in 1, suggesting that OAB refractory to
antimuscarinics may be caused by chronic inflammation.
Evidence that inflammatory processes are involved in the
pathogenesis of refractory OAB emerged from the investiga-
tions by the research group of Kuo who found that the inflam-
matory markers serum nerve growth factor (NGF), C-reactive
protein, and adipokines including interleukins and tumor ne-
crosis factor are increased in patients with refractory OAB [13,
25, 26]. Interestingly, elevated urinary NGF levels decreased
significantly in 39 women with refractory OAB after antibiot-
ic therapy, while the OAB symptoms daytime frequency,
nocturia, and urgency simultaneously improved significantly
[27]. Seventy four percent of these women also reported im-
provement in perception of their bladder condition.
Pharmacological reasons
Pharmacokinetics
After oral administration, bioavailability of the tertiary
antimuscarinic drugs darifenacin, oxybutynin, fesoterodine,
and tolterodine as well as of the quaternary drug trospium
chloride is characterized by a high intersubject variability
(Table 2) ([28–30], data on file 2013, Dr. R. Pfleger GmbH,
Bamberg, Germany). In the case of the ter t ia ry
antimuscarinics, individual pharmacokinetics may vary due
to genetic differences resulting in dissimilar metabolic degra-
dation by enzymes of the cytochrome P450 system [29, 31]. In
contrast, variability of bioavailability of trospium chloride is
primarily based on the relatively low rate of intestinal absorp-
tion [32], and excretion via bile and urine, where different
drug carriers seem to be involved [33, 34].
Furthermore, the pharmacokinetics of some antimuscarinic
drugs are influenced by food intake. Increased Cmax values of
the active drug were observed when oxybutynin, darifenacin,
and fesoterodine extended release were coadministered with a
high-fat meal [29, 31, 35], whereas decreased Cmax and AUC
values were calculated after ingestion of a high-fat meal to-
gether with trospium chloride [36].
Further factors which can influence the pharmacokinetics
of antimuscarinics include age, gender, and race (Table 3) as
well as hepatic and renal impairment. Since drug excretion via
the kidneys declines with age, Turnheim recommends treating
the elderly in general as renally insufficient patients [45].
Interactions
In addition to the described variations of the pharmacokinetics
of antimuscarinics, interactions with other simultaneously tak-
en drugs may lead to decreased or increased effects, thereby
Table 2 Intersubject variability of maximum plasma concentration
(Cmax) and area under the curve (AUC) values of different antimuscarinic
drugs under steady-state conditions
Reference
Variability of Cmax in %
Fesoterodine ER 33–48 Malhotra et al. [28]
Tolterodine ER 46–87 Malhotra et al. [28]
Trospium chloride IR 9–64 Data on file 2013,
Dr. R. Pfleger GmbH,
Bamberg
Variability of AUC in %
Darifenacin ER 48–71 % (EM) Skerjanec [29]
20–61 % (PM)
ER extended release, IR immediate release, PM poor metabolizers, EM
extensive metabolizers
Table 3 Influences of age, gender, and race on pharmacokinetics of







Age Darifenacin Yes Skerjanec [29]
Fesoterodine No Malhotra et al. [37]
Oxybutynin Increased
plasma levels
Hughes et al. [38]
Solifenacin AUC + 20 % Krauwinkel et al. [39]
Tolterodine No Wefer et al. [40]
Trospium
chloride
No Doroshyenko et al. [41]
Gender Darifenacin Lower CL
in women
Kerbusch et al. [42]
Fesoterodine No Malhotra et al. [37]
Oxybutynin No Lukkari et al. [43]
Solifenacin No Krauwinkel et al. [39]
Tolterodine No Guay [44]
Trospium
chloride
No Data on file 2013,








PK pharmacokinetics, BA bioavailability, CL clearance
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possibly limiting treatment efficacy or tolerability. It should be
taken into account that pharmacokinetic interactions may oc-
cur by competition in absorption, metabolic processes, and
excretion. Pharmacodynamic interactions may be caused
in particular by concomitant medication which can also
have additional anticholinergic potency. As shown by
Sumukadas et al., the proportion of older people with
a very high anticholinergic exposure increased from 7.3 % in
1995 to 9.9 % in 2010 [46]. It is known that a greater anticho-
linergic burden can lead to significant deficits in cognitive
function [47].
Muscarinic receptors
Pharmacodynamic reasons for refractory OAB could also be
based on the receptor level. Age-related decrease of musca-
rinic receptors in the urinary bladder has been shown in rats,
but there were only minor, if any, alterations in receptor re-
sponsiveness [48]. In humans, a shift of M3 muscarinic recep-
tor subtypes to M2 was observed in correlation with age and in
patients with neurogenic bladder overactivity [32]. Whether
such changes are of clinical relevance still remains to be
clarified.
All the described factors may necessitate adjustment of
individual doses in antimuscarinic treatment. A decrease of
the daily dose may be an option especially in elderly patients
when side effects become problematic, as physiological
changes connected with aging may result in reduced metabo-
lism, alterations in distribution, declined excretion, and a de-
cline in counter-regulatory mechanisms [45].
Pharmacological management of patients not responding
to first-line therapy
Generally, flexible dosing with antimuscarinics provides the
opportunity to increase or decrease the dose to meet the body
habitus and the pharmacokinetic and clinical needs of the
individual patients, thereby balancing efficacy against tolera-
bility [49]. In connection with this, discussion and exchange
of information between the physician and patient are a definite
requirement to define the individual dose.
Data collected from non-interventional studies show that
flexible dosing of trospium chloride adjusted to the patient’s
individual needs is commonly used in urological practices in
Germany (Fig. 1) (data on file, 2014 Dr. R. Pfleger GmbH,
Bamberg, Germany).
In patients who failed to respond, or showed suboptimal
response to antimuscarinic drugs but tolerated the treatment
well, it was shown that an increase of the daily dose may lead
to a significant improvement of the OAB symptoms. A sig-
nificant decrease of incontinence episodes was observed after
doubling the recommended daily doses of trospium
chloride and tolterodine to 90 and 8 mg, respectively,
in patients with persistent neurogenic detrusor overactiv-
ity (NDO) [8]. An alternative approach is the combina-
tion of two different antimuscarinic drugs, which has
been demonstrated as effective and safe in several clinical
studies including patients with either OAB or NDO [7,
50–53]. Combination of an antimuscarinic with a beta-3 ago-
nist has previously been investigated in clinical studies
(Table 4) [6, 54].
When assessing these study results in patients with refrac-
tory OAB, after doubling the recommended dose, or after
combination treatment with a second drug, or after replace-
ment by another antimuscarinic, one should consider that the
situation of the unsatisfactory response to behavioral and
antimuscarinic therapy is observed during daily routine med-
ical practice. Patients with OAB who are included in clinical
trials receive more intensive monitoring of their treatment.
Motivation of patients with OAB may be increased by a de-
fined regular follow-up appointment during clinical studies,
and specified selection criteria could lead to a relatively ho-
mogeneous patient population. Consequently, symptom im-






















Fig. 1 Different daily doses of
trospium chloride immediate
release tablets prescribed by
German urologists in 9,366
patients with OAB symptoms in
medical practices. Pooled data
from three non-interventional
studies carried out in Germany
(data on file, 2014, Dr. R. Pfleger
GmbH, Bamberg, Germany)
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during clinical practice, when antimuscarinic treatment is not
accompanied by close patient guidance [6]. This also
applies to trials involving patients with refractory OAB, where
treatment with an antimuscarinic drug was replaced by
another antimuscarinic or a beta-3 agonist, such as mirabegron
[6, 9].
However, dose adjustment, the combination of two differ-
ent antimuscarinic drugs, and replacement by another
antimuscarinic or a beta-3 agonist are options in order to im-
prove treatment success in individual patients with OAB. Se-
lection of the best tolerated drug is of great importance to
avoid unnecessary side effects. Especially in older patients
where co-medication can have its own anticholinergic effects
and/or compete in metabolism in the cytochrome P450 sys-
tem, impairment of cognitive function as a side effect, and
metabolic interactions, can largely be avoided by choosing
an appropriate antimuscarinic such as the quaternary molecule
trospium chloride, which does not seem to contribute to such
effects [55–58] and enables flexible dosing.
In patients in whom critical reassessment of diagnosis
leads to an exclusion of underlying causes for lower
urinary tract dysfunction and who do not respond to
intensive first-line therapy including adjusted antimuscarinic
treatment, the use of transcutaneous electrical nerve stimula-
tion, the intravesical administration of onabotulinumtoxinA
injections, or augmentation cystoplasty may be further treat-
ment options [59].
Conclusion
The incidence of refractory OAB seems to be
overestimated. An unsatisfactory improvement of symp-
toms in the first-line treatment option of patients with
OAB may depend on various factors. Realistic estima-
tion of treatment outcomes and side effects by the pa-
tient and/or the physician, individual patient guidance to
improve the patient’s motivation to adhere to treatment,
review of the OAB diagnosis, and exclusion of other
underlying causes as well as individual antimuscarinic
dose adjustment are procedures which can improve the
success of OAB therapy in daily medical practice. The
authors suggest using the term refractory OAB only in
such cases when the aforementioned steps have con-
firmed the patient’s nonresponse to first-line treatment
including antimuscarinic therapy.
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Table 4 Clinical studies using increased [8] or combined antimuscarinic treatment in patients with unsatisfactory benefit of previous/initial therapy
Medication at start of therapy Adjustment and dose/day Patients (n) Efficacy results Reference
Tolterodine 1×4 mg/day (n=11)
Trospium 3×15 mg/day (n=10)
Tolterodine 2×4 mg/day (n=11)
Trospium 3×30 mg/day (n=10)
NDO (21) In total UI episodes decreased
from 8–12 to 0–2




Plus trospium 45–90 mg
Plus oxybutynin 15–30 mg
Plus tolterodine 4–8 mg
NDO (27) UI episodes decreased:
From 8.6±2.7 to 1.3±0.9
From 7.0±1.5 to 0.6±0.7
From 7.5±2.7 to 2.0±1.5
Amend et al. [50]
Tolterodine 4 mg Plus solifenacin 5 mg
Plus solifenacin 10 mg
NDO (19)/OAB (14) UI episodes decreased:
By 100 % in 17 patients
By>90 % in 14 patients
By 50–89 % in 2 patients
Bolduc et al. [53]
Oxybutynin 15 mg/day
Oxybutynin 15 mg/day
Plus trospium 80 mg
Plus solifenacin 10 mg
NDO (12) Decrease of UI episodes:
From 5.3±SD to 0.8±SD
From 4.5±SD to 1.0±SD
Nardulli et al. [52]
Oxybutynin or
Tolterodine
Plus tolterodine ER 4 mg or
Plus solifenacin 5 mg or 10 mg
NDO/OAB
(31/25)
Decrease of UI episodes:
By 100 % in 23 patients
By>90 % in 18 patients
By 50–89 % in 15 patients
Nadeau et al. [7]
Trospium 60 mg plus
solifenacin 20 mg (198) or
Placebo (115)
OAB (313) Significant decrease in UI episodes
compared to placebo
Kosilov et al. [51]
Solifenacin 2.5, 5, or 10 mg or
Mirabegron 25 or 50 mg or
Solifenacin+mirabegron, or
Placebo
OAB (1306) Dose–response relationship for
MVV in all combination groups
No significant changes in UI
episodes compared to placebo
Abrams et al. [54]
UI urinary incontinence, NDO neurogenic detrusor overactivity,OAB overactive bladder (number of patients in parentheses), ER extended release,MVV
volume voided per micturition
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